Cellular FLICE-inhibitory protein (c-FLIP) inhibits death receptor-mediated apoptosis by specific interaction with FADD and procaspase-8, and may thus interfere with activation events mediated by FADD and caspase-8. Recent studies, however, suggest that c-FLIP also transmits activation signals. The role of c-FLIP on T-cell activation was examined here using several transgenic mice with variable c-FLIP expression. In all c-FLIP-transgenic mice, Fasmediated apoptosis and in vitro activation-induced T-cell death were suppressed, and T-cell proliferation and IL-2 production were inhibited. c-FLIP transgene also promoted in vivo thymocyte death. Higher c-FLIP transgene expression was correlated with a more profound suppression of T-cell activation and a prominent disturbance in mature thymocyte development. There was no evidence of increased activation and proliferation in all c-FLIP-transgenic T cells examined. Instead, suppression of T-cell activation in c-FLIP-transgenic T cells could be a combinatory effect of FADD/caspase-8-dependent signals and c-FLIP-specific activities.
Introduction
Engagement of death receptors (DRs) leads to formation of death receptor complexes first through the recruitment of FADD to DR, followed by the association of procaspase-8 (FLICE) with FADD due to interactions between the death effector domains (DEDs) of FADD and procaspase-8. The processing of procaspase-8 at the DR complexes generates caspase-8, which then cleaves other procaspases to produce a panel of effector caspases for apoptosis execution. 1, 2 Cellular FLICE-inhibitory protein (c-FLIP) specifically regulates the DR apoptotic process. [3] [4] [5] [6] [7] [8] [9] c-FLIP is expressed in both a long-form (c-FLIP L ) and a short-form (c-FLIP S ) due to alternative splicing. The DEDs of c-FLIP L and c-FLIP S interact with the DEDs of FADD and procaspasse-8. Through the binding of c-FLIP to FADD and procaspase-8 at the DR complexes, c-FLIP presumably prevents the processing of procaspase-8 and inhibits downstream apoptotic events. 10, 11 An intriguing issue regarding the physiological function of the DR apoptotic cascade is the involvement of FADD and caspase-8 in T-cell activation. 12 T cells from FADD-deficient chimeric mice and dominant-negative FADD-transgenic mice display profound inhibition of proliferation. [13] [14] [15] [16] [17] [18] [19] [20] T-cell activation is reported to stimulate caspase-8 and suppression of caspase-8 prevents T-cell activation. 21, 22 More recently, caspase-8 mutation in human and mouse was linked to defective lymphocyte activation and immunodeficiency. [23] [24] [25] These results suggested that FADD and caspase-8 are involved in the activation of naïve T cells, yet the activation signals mediated by FADD 17 and caspase-8 remain largely unknown.
It was thought that overexpression of c-FLIP, through binding to FADD and procaspase-8, must generate phenotypes similar to mice with inactivated FADD or caspase-8. However, different effects on T-cell activation were observed with mice overexpressing c-FLIP. 26, 27 In one group, T-cell activation was not affected by expression of c-FLIP in vivo. 26 In another study, c-FLIP-transgenic T cells displayed increased proliferation when stimulated with low concentrations of anti-CD3, and decreased proliferation when activated with high concentrations of anti-CD3. 27 Activation of extracellular signal-regulated kinase (ERK) and NF-kB and IL-2 production were also found to increase in the same c-FLIP-transgenic T cells. 28 For the latter observation, it was proposed that FADD participates in T-cell activation by the recruitment of c-FLIP and c-FLIP-associated signaling molecules, 10 and failure to recruit c-FLIP in the absence of functional FADD leads to Tcell inactivation.
In this study, we generated c-FLIP-transgenic mice to study the exact effect of c-FLIP overexpression on T-cell activation. Fas-induced apoptosis and in vitro activation-induced cell death (AICD) were inhibited in c-FLIP-transgenic mice. T-cell proliferation and IL-2 production were suppressed in all c-FLIP-transgenic mice. At different concentrations of TCR stimulants, we failed to detect any increase in proliferation and IL-2 production in T cells from all c-FLIP-transgenic mice. Our results do not support a direct activation role of c-FLIP in T-cell activation. We found that c-FLIP also transmitted signals independent of FADD and caspase-8. Together with c-FLIP-mediated inactivation of FADD and caspase-8, c-FLIP overexpression effectively inhibited T-cell activation.
Results

Variable expression of c-FLIP transgene
Human c-FLIP L was subcloned into the p1017 vector with the lck proximal promoter or into the CD2 cassette with the CD2 locus control region 29 Figure 1c ) or low-expression (represented by FLIP-4 in Figure 1c ). FLIP-1 was generated from the C57BL/6 strain of mice, while FLIP-2, FLIP-3, and FLIP-4 were produced from the FVB strain of mice. We generated a total of nine independent transgenic mouse lines. All results described below are from CD2-c-FLIP L -transgenic mice.
Nearly identical results were observed with lck-c-FLIP Ltransgenic mice.
Thymus from c-FLIP-transgenic mice were smaller than their normal littermate control (NLC) mice in FVB strain (Table 1) . Thymus size and total thymocyte number were affected to a greater degree in high c-FLIP-expressing transgenic mice than low c-FLIP-expressing mice. The extent of reduction in total thymocyte number seemed to correlate with the expression level of c-FLIP.
Normal in vivo AICD and suppressed in vitro AICD in FLIP-transgenic T cells We next examined whether in vitro AICD, known to be Fasmediated, [30] [31] [32] [33] was affected by FLIP transgene. NLC thymocytes stimulated with anti-CD3 underwent apoptosis, yet c- c-FLIP transgene suppresses T-cell proliferation and AICD T-S Tai et al FLIP-transgenic thymocytes were resistant to AICD (Figure 2b ). We also examined the sensitivity to AICD in mature T cells. Splenic T cells and lymph node T cells were activated with anti-CD3/anti-CD28, followed by IL-2 incubation for 4 additional days. Preactivated splenic T cells from NLC mice were more sensitive to death induced by low concentrations of anti-CD3 than thymocytes (Figure 2c ). Transgenic expression of c-FLIP completely suppressed anti-CD3-induced death in preactivated splenic T cells. An equally effective inhibition of AICD was found in lymph node T cells from c-FLIP-transgenic mice (Figure 2d ). Inhibition of in vitro activation-induced apoptosis was found in all the c-FLIPtransgenic mice lines that we analyzed. In contrast to suppression of Fas-mediated apoptosis in c-FLIP-transgenic thymocytes, in vitro thymocyte death by neglect was elevated in c-FLIP-transgenic thymocytes. Progressive cell death observed upon in vitro culture of thymocytes was similar between NLC and c-FLIP-transgenic thymocytes during the first day of incubation (Figure 4a ), as observed also for the background death of thymocyte AICD (Figure 2b ). There was an increased apoptosis for c-FLIPtransgenic thymocytes compared to NLC thymocyte after 2 days of incubation. The elevation in c-FLIP-transgenic thymocyte death was moderate, with an increase of 10-15% over NLC thymocytes 4 days after in vitro incubation (Figure 4a) . To determine the effect of c-FLIP expression on thymocyte death in vivo, thymocytes were isolated from NLC and c-FLIP-transgenic mice and the frequency of apoptosis was immediately quantitated. Such measurement underestimated the actual apoptosis, as apoptotic cells are rapidly engulfed, yet a clear difference in apoptosis was observed between normal and c-FLIP-transgenic thymocytes. The frequency of apoptotic cells in normal thymocytes was 1.5%, which was increased to 3.4% in thymocytes from c-FLIPtransgenic mice (Figure 4b ). Elevation of apoptosis in vivo was similar in CD4
thymocytes from c-FLIP-transgenic mice (Figure 4c ), suggesting that the increase in cell death was independent of the maturation stage of thymocytes.
Suppression of proliferation and IL-2 expression with c-FLIP-transgenic T cells
We then determined whether the c-FLIP expression could lead to the proliferation defects seen with FADD-deficient, DN-FADD, or caspase-8-deficient T cells. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Activationinduced thymocyte proliferation was reduced in c-FLIPtransgenic mice, when activated with anti-CD3/anti-CD28, Con A, or TPA/A23187 ( IL-2 production, another major T-cell activation indicator, was analyzed in c-FLIP-transgenic T cells stimulated by ant-CD3. IL-2 production from FLIP-transgenic thymocytes was consistently lower than NLC thymocytes (Figure 5d ). Therefore, ectopic c-FLIP expression led to reduced T-cell proliferation and decreased IL-2 expression. Inhibition of Tcell activation was more profound in transgenic T cells with high levels of c-FLIP than T cells with lower contents of the c-FLIP transgene (FLIP-hi and FLIP-lo in Figure 5e ). In addition, suppression of T-cell proliferation by the c-FLIP transgene was found in CD4 þ as well as CD8 þ splenic T cells (data not shown).
Reduced activation of ERK, p38 MAPK, and NF-jB in c-FLIP-transgenic T cells
The decrease in T-cell proliferation and IL-2 production suggested a defect in T-cell activation signaling. Some key activation molecules, including ERK, NF-kB, and p38 MAPK, were examined before and after stimulation of c-FLIPtransgenic splenic T cells with TPA/A23187 or anti-CD3/ anti-CD28. ERK activation, detected by a phospho-ERKspecific antibody, was significantly reduced in FLIP-transgenic thymocytes activated through TPA/A23187 (Figure 6a ) or CD3/CD28 (Figure 6b ). NF-kB activation was monitored by þ CD8 þ thymocytes when compared to NLC mice (Figure 8a, B6) . The disturbance for thymocyte development by c-FLIP was more evident on FVB mice than on C57BL/6 mice, due to the presence of higher proportions of single positive thymocytes in FVB mice. The CD4 þ CD8 À thymocytes were reduced from 16.2 to 11.2%, and the CD4 À CD8 þ thymocytes were decreased from 4.2 to 2.6% in transgenic mice with elevated c-FLIP transgene expression (Figure 8a, FVB-hi) . The disturbance of thymocyte development was more conspicuous when the absolute cell numbers of individual thymic subpopulation from six pairs of FVB mice were compared (Table 1) . In transgenic mice with high c-FLIP expression, CD4 À CD8 þ thymocytes were decreased from 3.6 Â 10 6 to 1.8 Â 10 6 cells and CD4 þ CD8 À thymocytes reduced from 15.4 Â 10 6 to 5.9 Â 10 6 cells. In contrast, the thymocyte profile (Figure 8a , FVB-lo) of transgenic mice with low c-FLIP expression levels was almost indistinguishable from those of NLC mice. Fractions of the peripheral mature T cells were also reduced in transgenic mice with high c-FLIP expression (Figure 8b ), likely to have resulted from impaired development of CD4 þ CD8 À and CD4 À CD8 þ thymocytes. The percentage of splenic CD4 þ T cells in c-FLIP-transgenic mice was reduced from 34 to 24% in FVB mice, concurrent with CD8 þ T cells decreasing from 10 to 7% (Figure 8b , FVBhi). In contrast, a smaller disturbance in splenic T-cell development was found in transgenic lines with lower levels of c-FLIP expression (Figure 8b, FVB-lo) . Therefore, perturbation of T-cell development was more prominent in mice with We further elucidated whether a reduction in mature thymocytes might be attributed to attenuated T-cell activation in mice with high level of c-FLIP transgene. Thymocyte positive selection is correlated with increased expression of CD69. The frequency of CD69 þ thymocytes was lower in c-FLIP-transgenic mice than in NLC mice (Figure 9a ). Among CD4 þ CD8 À and CD4 À CD8 þ thymocytes, the fractions of CD69 þ populations were reduced in c-FLIP-transgenic mice compared to normal mice. The development of CD4 þ CD8 À thymocytes into mature thymocytes was also marked by upregulation of CD5, class I MHC, and TCR. There was a clear reduction in the fraction of CD5 þ , class I MHC þ , and TCR þ in CD4 þ CD8 À and CD4 À CD8 þ thymocytes from c-FLIP-transgenic mice, even though the mean intensity of CD5 and CD69 was not significantly altered (Figure 9b ). There was a moderate decrease in the TCR level in c-FLIP-transgenic mice. Therefore, the decrease in mature T lymphocytes in c-FLIP-transgenic mice was partly linked to reduced TCRmediated selection.
Discussion
FADD and caspase-8 are known to be essential for T-cell activation; however, the activation signals transmitted by FADD and caspase-8 are poorly understood. 25 In this study, we produced transgenic mice with T-cell-specific expression of c-FLIP, the specific inhibitor of FADD and caspase-8, to examine how T-cell activation would be affected. Despite the variation in c-FLIP transgene expression, Fas-mediated apoptosis and in vitro AICD were suppressed in all transgenic T cells (Figure 2) . Therefore, even low levels of c-FLIP transgene conferred resistance of T lymphocytes to Fasinduced cell death. In addition, we observed suppressed proliferation of T cells in all transgenic mice ( Figure 5 ). Defective proliferation is found in T cells from FADD-deficient chimeric mice and dominant-negative FADD-transgenic mice, [13] [14] [15] [16] [17] [18] [19] [20] and in T cells with inactivated caspase-8.
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Overexpression of c-FLIP, therefore, results in T-cell proliferation defects similar to those with FADD and caspase-8 inactivation. FADDÀ/À T cells are also characteristic for cycling before TCR ligation and for the enhanced p21 induction the suppressed cyclin D2 expression after TCR stimulation. 18 The spontaneous T-cell cycling, increased p21 induction, and reduced cyclin D2 expression were also detectable in c-FLIP-transgenic mice (Figure 7) . We propose that part of the activation defect observed in c-FLIPtransgenic T cells is due to neutralization of FADD or caspase-8 by c-FLIP.
c-FLIP-transgenic T cells also exhibited signaling defects not found in FADDÀ/À or caspase-8-deficient T cells. Reduced IL-2 expression was found in c-FLIP-transgenic mice ( Figure 5 ), but not in FADDÀ/À or DN-FADD T cells. 15, 17, 19 In addition, in our studies, ERK, p38 MAPK, NF-kB activation was attenuated in c-FLIP-transgenic T cells (Figure 6 ), yet is normal in DN-FADD T cells and caspase-8-deficient T cells. 17, 19, 24 There were also effects that were not easily assigned to either FADD or caspase-8. For example, resting FADDÀ/À T cells exhibit a constitutive expression of cyclin E and cdk2, 18 yet the levels of cyclin E and cdk2 were nearly normal in c-FLIP-transgenic T cells (Figure 7b ). Overall, the suppression of T-cell activation seen in c-FLIPtransgenic mice cannot be fully accounted for by inhibition of FADD or caspase-8. Interestingly, inhibition of IL-2 production, seen in c-FLIP-transgenic T cells (Figure 5 ), has also been observed in T cells treated with caspase-8 inhibitors, 21 T cells from patients with defective caspase-8, 23 and T cells from caspase-8-deficient mice. 24 Whether the defective IL-2 expression in c-FLIP-transgenic T cells could be attributed to an inactivated caspase-8 deserves further investigation. We also observed that high level of c-FLIP expression disturbed T-cell development ( Figure 8 and Table 1 ). Reduction was prominent in CD4 þ CD8 À and CD4 À CD8 þ thymocyte subpopulations, both in their frequencies (Figure 8a ) and in absolute cell numbers (Table 1) for mice expressing high levels of the c-FLIP transgene. A similar decrease in CD4 þ CD8 À and CD4 À CD8 þ thymocytes was found previously in c-FLIP-transgenic mice (Figure 4 in Lens et al. 27 ). In contrast, interference with thymocyte development was not (Table 1 and Figure 8 ), despite Fas-mediated apoptosis being effectively suppressed in these T cells. The ability of c-FLIP to antagonize Fas-induced apoptosis, therefore, is dissociated from the effect of c-FLIP on thymocyte development. We speculate that the impaired thymocyte development is likely linked to the suppressed T-cell activation in the presence of c-FLIP overexpression. T-cell proliferation was inhibited to a (Figure 5e ). In addition, there was a significant reduction in mature thymocytes expressing CD69, CD5, class I MHC and TCR in mice overexpressing c-FLIP (Figure 9 ). Attenuation of TCR-initiated activation signals in c-FLIPtransgenic thymocytes ( Figure 6 ) may result in reduced TCRmediated selection of the CD4 þ CD8 þ thymocytes, leading to a decrease in mature thymocytes and peripheral T cells (Figure 8) .
Similar to the disturbance of thymocyte development, a decrease in thymocyte number also correlated with expression levels of c-FLIP (Table 1) . That transgenic expression of c-FLIP and v-FLIP leads to a reduction in thymocyte numbers has also been previously documented. 27, 34 At least two different mechanisms may be proposed for the reduction in thymocyte number as a consequence of elevated c-FLIP expression. First, elevated c-FLIP suppresses T-cell activation to a greater extent (Figure 5e ), resulting in diminished survival signals and decreased thymocyte survival. Second, c-FLIP has been shown to exhibit proapoptotic effect. 4, 6, 8, 9, 37, 38 Consistent with these reports, we found an increase in the death of thymocytes from transgenic mice with c-FLIP overexpression (Figure 4) , likely contributing to the reduction in total thymocyte number in c-FLIP-transgenic mice. It may be noted that apoptosis induced by c-FLIP overexpression was independent of the developmental stage of thymocytes; increased cell death was found in immature as well as in mature thymocyte populations (Figure 4) , which may explain why the number of CD4 À CD8 À thymocyte was also reduced in c-FLIP-transgenic mice ( Table 1) .
The in vivo activation-induced death of T cells, including thymocyte negative selection, is known to be Bim-dependent but Fas-independent. 35, 36 Therefore, overexpression of c-FLIP was not expected to interfere with in vivo AICD, as observed in this and previous c-FLIP-transgenic studies. 27 In the present study, c-FLIP effectively suppressed the in vitro AICD in all transgenic T cells we generated (Figure 2 ). Fas-FasL interaction plays a dominant role in the in vitro activation-induced T-cell death.
1,30-33 c-FLIP expression, which blocks T-cell activation, may prevent in vitro activation-induced T-cell death through inhibition of activationinduced FasL expression and Fas upregulation.
The effect of c-FLIP overexpression on T-cell development (Figures 8 and 9 ) is distinct from the inactivation of FADD or caspase-8, suggesting that some of the c-FLIP biological activities are not mediated by neutralization of FADD and caspase-8 alone. The exact mechanisms on how c-FLIP suppresses T-cell activation and T-cell development deserve further characterization. In contrast, c-FLIP was recently reported to promote T-cell activation and lead to increased Tcell proliferation and IL-2 production. 27, 28 We did not detect these stimulatory effects of c-FLIP in the nine transgenic lines we produced. Instead, increased suppression of T-cell proliferation correlates with an elevated expression of the c-FLIP transgene (Figure 5e ), suggesting an inhibitory nature of c-FLIP overexpression on T-cell activation. Since the reported enhanced proliferation was observed only when c-FLIPtransgenic T cells were stimulated by low concentrations of anti-CD3 or antigen, 27 minimum activating concentrations of anti-CD3 and Con A were thus used to stimulate c-FLIPtransgenic splenic T cells. However, suppression of T-cell proliferation was consistently observed with c-FLIP-transgenic T cells (Figure 5c ). In addition, the several T-cell activation signals examined decreased in c-FLIP-transgenic T cells compared to normal T cells (Figure 6 ). Despite the report that c-FLIP couples to Raf-1 for ERK activation, and binds to TRAF1/TRAF2 for NF-kB activation, 22 we found no ERK activity or NF-kB activation in the resting c-FLIP-transgenic T lymphocytes ( Figure 6 ). In contrast, ERK activity and NF-kB activation were attenuated in c-FLIP-transgenic T cells ( Figure 6 ). Dissociation of c-FLIP expression from NF-kB activation has also been supported by recent studies. 39, 40 NFkB activation is not reduced in c-FLIP-deficient cells. 39 c-FLIP is unable to activate IkB kinase complex in primary effusion lymphoma. 40 All the above-mentioned discrepancies could be due to differences in the expression level of c-FLIP transgene, yet also illustrate that c-FLIP overexpression does not necessarily lead to increased T-cell proliferation and elevated ERK/NF-kB activation.
In summary, expression of c-FLIP, even at a low level, prevented Fas-mediated apoptosis and inhibited T-cell proliferation and IL-2 production. High levels of c-FLIP expression also led to disturbed T-cell development, likely caused by effective suppression of TCR-initiated activated signals. Our results also suggest that c-FLIP expression does not necessarily promote T-cell proliferation and increase T-cell activation. The ability to activate signals is probably not an inherent property associated with c-FLIP. Instead, increased c-FLIP expression results in T-cell inactivation. The inhibitory effect of c-FLIP on T-cell activation could be partly attributed to inactivation of FADD or caspase-8. c-FLIP may thus be a useful tool to elucidate some of the activation signals transmitted by FADD and caspase-8. However, c-FLIP also stimulates signals that are independent of FADD and caspase-8, contributing to events such as enhanced thymocyte death and suppressed thymocyte maturation. The overall phenotype of c-FLIP expression in vivo is likely a summation of physiological effects from both FADD/caspase-8 inactivation and c-FLIP-specific signals.
Materials and Methods
Reagents and cell lines
Con A, TPA, and A23187 were purchased from Sigma Chemical Co. (St. Louis, MO, USA). The following antibodies were purchased from Caltag (Burlingame, CA, USA): mouse CD4 (clone CT-CD4, FITC-or TriColorconjugated), CD5.2 (clone CG16, FITC-conjugated), CD8 (clone CTCD8a, PE, or TriColor-conjugated), CD69 (clone H1.2F3, FITCconjugated), and TCR (H57-597, FITC-conjugated). PE-conjugated anti-CD4 (GK1.5) and FITC-labeled anti-CD8 (53-6.7) were purchased from eBioscience (San Diego, CA, USA). FITC-conjugated anti-D q was obtained from BD-PharMingen (San Diego, CA, USA). Splenic T lymphocytes were isolated by panning twice on plates precoated with goat anti-mouse Ig antibody (Sigma) and the purity was confirmed by FACS to be 492%. For studies on activation-induced apoptosis, splenic T cells were activated with anti-CD3/anti-CD28 for 24 h. Activated splenic T cells were then washed and incubated in the presence of IL-2 (10 U/ml) for another 4 days before anti-CD3 treatment.
Plasmids
Preparation of c-FLIP L cDNA was previously described. 41 p1017 containing the lck 3.2 kb proximal promoter and 3 0 untranslated region of growth hormone (mini gene exons 1-5) was a gift from Dr. Roger Perlmutter (University of Washington, Seattle). The human CD2 cassette 29 was a gift from Dr. Dimitris Kioussis (National Institute for Medical Research, London). Transgenic mice were generated in the transgene/knockout core of Institute of Molecular Biology, Academia Sinica (Taipei, Taiwan). p1017-c-FLIP L , and CD2-c-FLIP L were microinjected into the pronuclei of both C57BL/6 and FVB zygotes. Nine independent founders were obtained. All transgenic mice were maintained in the SPF mice facility of Institute of Molecular Biology, Academia Sinica. All mice experiments were approved by the Experimental Animal Committee, Academia Sinica.
Cell death measurement
All cultures were performed in RPMI with 10% fetal calf serum (both from GIBCO, Grand Island, NY, USA), 10 mM glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, and 2 Â 10 À5 M 2-ME. The extent of apoptosis was determined by propidium iodide (PI) staining. At the end of different treatments, cells were resuspended in hypotonic fluorochrome solution (50 mg/ml PI, 0.1% sodium citrate, 0.1% Triton X-100), 42 and placed at 41C in the dark overnight. DNA contents were analyzed by FACScan (Becton Dickinson, Mountain View, CA, USA). Fraction of cells with sub-G1 DNA content was assessed using the CELLFIT software program (Becton Dickinson).
Nuclear extract and total cell extract T cells were lysed in 10 mM Tris-HCl (pH 7.4), 10 mM NaCl, 3 mM MgCl 2 , and 0.5% Nonidet P-40 (NP-40). The lysates were incubated on ice for 5 min and were centrifuged at 1500 rpm for 5 min at 41C. The pellet (nuclei) was suspended in hypertonic buffer containing 20 mM HEPES (pH 7.9), 1.5 mM MgCl 2 , 0.3 M KCl, 0.5 mM DTT, 1 mM PMSF, 20% glycerol, and 0.4 mM EDTA, and agitated at 41C for more than 30 min. The mixture was centrifuged at 13 000 rpm for 10 min. The supernatant was then mixed with two volumes of the above buffer (without KCl) and frozen immediately. Total cell extracts were prepared by resuspending cells in hypotonic buffer containing 10 mM HEPES (pH 7.9), 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 0.5 mM PMSF, 100 mg/ml aprotinin, 1.25 mg/ml leupeptin, and lysed by three cycles of freezing and thawing. One-tenth volume of 3 M KCl was then added, and the lysates agitated at 41C for 30 min. Lysates were obtained following the same procedures as those used for isolation of nuclear extracts. Protein concentrations were determined by Bradford assay (Bio-Rad, Richmond, CA, USA).
Immunoblot
Cell extracts (30-50 mg) were resolved by 10% SDS-PAGE and transferred to PVDF membranes (Millipore, Bedford, MA, USA) for 4 h at 20 V. Membranes were washed in rinse buffer (PBS with 2% Tween 20) at room temperature for 15 min and incubated in blocking buffer (5% nonfat milk in rinse buffer) for 1.5 h. The membrane was then incubated with primary antibody for 2 h at room temperature and afterwards washed three times with rinse buffer. The membrane was then incubated with 1 : 1000 diluted horseradish peroxidase-conjugated anti-rabbit Ig antibody (Santa Cruz) followed by development with ECL reagents (Amersham, Buckinghamshore, UK). The primary antibodies used were: anti-FLIPS/L (H-202), anti-ERK2 (C-14), anti-p38a (C-20) (from Santa Cruz Biotech, Santa Cruz, CA, USA); anti-phospho (T202/Y204) ERK, anti-phospho (T180/Y182) p38 MAPK, anti-phospho IkB (from Cell Signaling, Beverly, MA, USA). All antibodies against cell cycle protein were obtained from Santa Cruz.
